Predictors of Response and Survival Outcomes of Triple Negative Breast Cancer Receiving Neoadjuvant Chemotherapy
Conclusions: Insights into the chemo-resistance mechanisms and exploration of novel targeted agents in subgroups as per AR and Ki-67 status are needed to improve survival outcomes in TNBC patients.Chemotherapy (Source: Chemotherapy)
Source: Chemotherapy - September 7, 2020 Category: Cancer & Oncology Source Type: research
A Prospective Study on the Usefulness of Initial Voriconazole Dose Adjustment Based on CYP2C19 Gene Polymorphism Analysis
In this study, we prospectively evaluated the usefulness of CYP2C19 polymorphism analysis in adjusting the initial VRCZ maintenance dose. The study enrolled 19 patients who underwent analysis of CYP2C19 polymorphism prior to VRCZ administration. Subjects were classified into 3 phenotype subgroups: extensive metabolizer (EM), intermediate metabolizer (IM), and poor metabolizer (PM). The initial VRCZ maintenance doses given twice daily were proposed as follows: approximately 8, 6, and 4 mg/kg/day for EM, IM and PM, respectively, according to previous reports. In EM, the initial maintenance dose was 8.0 ± 0.5 mg/kg/day, and ...
Source: Chemotherapy - September 2, 2020 Category: Cancer & Oncology Source Type: research
Publisher's Note
Chemotherapy (Source: Chemotherapy)
Source: Chemotherapy - September 1, 2020 Category: Cancer & Oncology Source Type: research
Further Analytical, Pharmacokinetic, and Clinical Observations on Low-Dose Ponatinib in Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
Conclusions: We developed a highly sensitive and selective HPLC-MS/MS method to quantify PNT in human plasma. This method might be used for TDM and to guide dose reductions if unnecessary high PNT levels are detected in a patient.Chemotherapy (Source: Chemotherapy)
Source: Chemotherapy - August 21, 2020 Category: Cancer & Oncology Source Type: research
High-Risk Recurrence Basal Cell Carcinoma: Focus on Hedgehog Pathway Inhibitors and Review of the Literature
Basal cell carcinoma is the most common skin tumour, with the majority of the cases occurring on the head and neck district, where cosmetic and functional results are crucial. It can be locally destructive if not diagnosed early and treated appropriately. Surgery is the treatment of choice for most lesions, but aggressive, recurrent, or unresectable tumours can be challenging to manage. Advanced basal cell carcinoma includes high recurrence risk subtypes, in which standard therapies demonstrate lack of efficacy. This led to a need for investigating more deeply the pathogenesis of the disease and to the discovery of the imp...
Source: Chemotherapy - August 10, 2020 Category: Cancer & Oncology Source Type: research
Melatonin Administered before or after a Cytotoxic Drug Increases Mammary Cancer Stabilization Rates in HER2/Neu Mice
Conclusions: MT supplementation to cytotoxic drugs can improve antitumor response, especially if it is blunted because of an inappropriate time of administration.Chemotherapy (Source: Chemotherapy)
Source: Chemotherapy - August 7, 2020 Category: Cancer & Oncology Source Type: research
Phase II Study of Weekly Nanoparticle Albumin-Bound Paclitaxel as Second- or Third-Line Therapy in Patients with Advanced Non-Small Cell Lung Cancer
Conclusions: Nab-PTX may be a later-line chemotherapeutic option for previously treated advanced NSCLC.Chemotherapy (Source: Chemotherapy)
Source: Chemotherapy - July 16, 2020 Category: Cancer & Oncology Source Type: research
Risk Associated with Severe Hematological Toxicity in Patients with Urothelial Cancer Receiving Combination Chemotherapy of Gemcitabine and Cisplatin
Conclusions: PS ≥ 1, neutrophil count, PLT, andK level were important risk factors for GC therapy-induced hematological toxicity in patients with UC. To continue GC therapy, further management systems by hematological toxicity risk factors for patients with UC will be required.Chemotherapy (Source: Chemotherapy)
Source: Chemotherapy - July 15, 2020 Category: Cancer & Oncology Source Type: research
Contents Vol. 64, 2019
Chemotherapy 2019;64:I –V (Source: Chemotherapy)
Source: Chemotherapy - July 7, 2020 Category: Cancer & Oncology Source Type: research
Acknowledgement to Reviewers
Chemotherapy 2019;64:270 (Source: Chemotherapy)
Source: Chemotherapy - July 7, 2020 Category: Cancer & Oncology Source Type: research
Rare Case of Endoscopic Treatment for Bevacizumab-Related Gastric Perforation in a Patient with Ovarian Cancer
We present a rare case of bevacizumab-induced gastric perforation in a patient with advanced OC occurred during bevacizumab-including chemotherapy in an adjuvant setting. Surgical treatment was not possible due to the frailty of the clinical condition of the patient and the gastric perforation was successfully treated with endoscopic suturing.Chemotherapy (Source: Chemotherapy)
Source: Chemotherapy - July 2, 2020 Category: Cancer & Oncology Source Type: research
Sustained Complete Remission with Incomplete Hematologic Recovery (CRi) in a Patient with Relapsed AML and Concurrent BCR-ABL1 and CBFB Rearrangement Treated with a Combination of Venetoclax and 5-Azacytidine
The co-occurrence ofBCR-ABL1 fusion and core-binding factor (CBF) rearrangements is uncommonly reported in AML. Although CBF rearrangements carry a favorable prognosis, the coexistence ofBCR-ABL1 is associated with aggressive disease suggesting a potential advantage of high-intensity chemotherapy in association with tyrosine kinase inhibitors. Herein, we describe a refractory AML patient harboringBCR-ABL1 fusion and CBFB rearrangement that was successfully treated with a combination of venetoclax and hypomethylating agent.Chemotherapy (Source: Chemotherapy)
Source: Chemotherapy - June 22, 2020 Category: Cancer & Oncology Source Type: research
Comparison of Platinum/S-1 and Platinum/5-Fluorouracil as First-Line Chemotherapy for Advanced Gastric or Gastroesophageal Junction Cancer: A Meta-Analysis Based on Randomized Controlled Trials
Conclusions: PF and PS show similar antitumor efficacy (OS, PFS, ORR, and DCR), but patients receiving PS exhibit longer TTF and fewer AEs (stomatitis, nausea, and hypokalemia) than those receiving PF.Chemotherapy (Source: Chemotherapy)
Source: Chemotherapy - June 12, 2020 Category: Cancer & Oncology Source Type: research
When Poisons Cure: The Case of Arsenic in Acute Promyelocytic Leukemia
Arsenic has been known for centuries for its double-edged potential: a poison and at the same time a therapeutic agent. The name “arsenikon,” meaning “potent,” speaks itself for the pharmaceutical properties of this compound, questioned and analyzed for at least 2000 years. In the last decades, acute promyelocytic leukemia (APL) has evolved from a highly fatal to a curable disease, due to the use of all-trans-retinoic acid and, more recently, arsenic trioxide combinations. The success of these entirely chemo-free regimens increased the awareness of APL and reduced the prevalence of early deaths, which was an impend...
Source: Chemotherapy - June 10, 2020 Category: Cancer & Oncology Source Type: research
The First Report on Pharmacokinetic/Pharmacodynamic Study of Trimethoprim/Sulfamethoxazole against < b > < i > Staphylococcus aureus < /i > < /b > with a Neutropenic Murine Thigh Infection Model
Conclusions: The TMP/SMX treatment demonstrated that the free AUC/MIC of SMX was the better predictor of the PK/PD index of TMP/SMX.Chemotherapy 2019;64:224 –232 (Source: Chemotherapy)
Source: Chemotherapy - May 20, 2020 Category: Cancer & Oncology Source Type: research
